简体
简体中文
繁體中文

林赛 LNN

等待开盘 02-04 09:30:00 美东时间

126.765

-0.505

-0.40%

华盛通华盛通
立即下载
  • 最 高129.25
  • 今 开126.10
  • 成交量 4.89万股
  • 最 低 125.93
  • 昨 收 127.27
  • 总市值 13.43亿
  • 52周最高 150.22
  • 市盈率 18.69
  • 换手率 0.46%
  • 52周最低 106.10
  • 委 比 20.00%
  • 总股本 1059.20万
  • 历史最高 178.82
  • 量 比 0.85
  • 振 幅 2.61%
  • 历史最低 31.16
  • 每 手 1
  • 风险率 9.23%

个股概要

财务分析

公司资料

相关新闻

分红派息

  • 分时图
  • 日k
  • 周k
  • 月k

相关新闻

更多
  • Palomar Holdings, Inc. Announces Fourth Quarter and Full Year 2025 Financial Results Release Date and Conference Call

    Palomar Holdings, Inc. announced it will release its fourth quarter and full year 2025 results on February 11, 2026, followed by a conference call on February 12 at 12:00 p.m. ET. The call can be accessed via 1-877-423-9813 (US) or 1-201-689-8573 (int'l), and a replay will be available starting February 12 at 4:00 p.m. ET through February 19. A live webcast is also available on the company's investor relations website. Palomar is a specialty insu...

    02-02 21:30

  • 美国联邦政府面临部分停摆 参议院拨款表决陷入僵持

      由于参议院在推进旨在维持联邦机构运行的拨款协议投票时陷入僵局,美国政府正面临最早于当地时间周六凌晨开始至少是一次简短的、部分停摆的风险。参议院共和党人表示...

    01-31 07:05

  • Cardiff Oncology Appoints Mani Mohindru as Interim CEO Amid Leadership Transition

    Cardiff Oncology Appoints Mani Mohindru as Interim CEO Amid Leadership Transition Cardiff Oncology Inc. has announced executive leadership changes as it moves toward late-stage clinical development. Mani Mohindru, PhD, has been appointed interim Chief Executive Officer, replacing Mark Erlander, PhD.

    01-27 23:00

  • Adagene Provides Business Update and 2026 Objectives

    Adagene Inc. reported unaudited cash of $74.5M as of Dec 31, 2025, providing runway into late 2027. Key 2025 achievements include Phase 1b/2 trial results for muzastotug in MSS CRC, FDA Fast Track designation for muzastotug + pembrolizumab, regulatory alignment with FDA, and initiation of a randomized Phase 2 trial. Strategic partnerships with Sanofi, Third Arc Bio, Exelixis, and ConjugateBio advanced masked antibody therapies. 2026 objectives in...

    01-23 13:00

  • Manitowoc Appoints Mark Rourke and Randy Wood to Board of Directors

    Manitowoc Appoints Mark Rourke and Randy Wood to Board of Directors The Manitowoc Company, Inc. has appointed Mark B. Rourke and Randy A. Wood to its board of directors, effective immediately. Rourke is the President and CEO of Schneider National, while Wood is the President and CEO of Lindsay Corpo

    01-21 22:01

  • 电话会总结 | Lindsay(LNN)2026财年Q1业绩电话会核心要点

    <span style="color:#999999;">编者按:聚焦公司高管观点与展望,深挖业绩背后的信息,助力投资者把握先机。</span><blockquote><p><span style="color:#fa1432;"><strong>业绩回顾</strong></span></p></blockquote><p>&#8226; 根据Lindsay业绩会实录,以下是财务业绩回顾摘要: ## 1. 财务业绩 **总体业绩表现:** - 总营收1.558亿美元,同比下降6%,主要受灌溉业务量下降影响,但基础设施业务增长部分抵消了下滑 - 营业收入1,960万美元,同比下降6%,营业利润率维持在12.6%,与去年同期持平 - 净利润1,650万美元,每股收益1.54美元,均较去年同期略有下降 - 自由现金流受营运资本增加和资本支出水平上升影响 **分业务板块表现:** - 灌溉业务营收1.334亿美元,同比下降9%;其中美国市场下降4%,国际市场下降1,030万美元 - 灌溉业务营

    01-16 12:01

  • 美股大行评级 | 瑞穗上调英伟达、谷歌、美光科技、SanDisk多家科技股目标价;中金首予诺和诺德"跑赢大市"评级,目标价73.5美元

    今日重点评级关注:Needham:维持Cartesian Therapeutics"买入"评级,目标价从40美元升至42美元;Piper Sandler:维持Acrivon Therapeutics"超配"评级,目标价从6美元升至8美元

    01-12 14:09

  • Lindsay Corp Earnings Call Balances Caution and Confidence

    Lindsay Corp. (($LNN)) has held its Q1 earnings call. Read on for the main high...

    01-10 08:07

  • Lindsay Corp. Earnings Call: Margins Steady, Demand Soft

    Lindsay Corp. (($LNN)) has held its Q1 earnings call. Read on for the main high...

    01-10 08:02

  • Stifel Maintains Hold on Lindsay, Raises Price Target to $128

    Stifel analyst Nathan Jones maintains Lindsay (NYSE:LNN) with a Hold and raises the price target from $122 to $128.

    01-09 22:29